---
run_id: halo-evidence-vs-diagnosis-validation-v11-generic-advice-prompted-01
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
model_condition: generic_advice_prompted
run_number: 1
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 1024
seed: 105
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 18fa1d51f6167dbbf1f7ece676734d5cdb459384bca25e1508dd96cd4745e42d
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 31fa87bc7ee0d210ab5e0070b5421b72beac068fc006b3bc3be78b3dd242d5e7
condition_packet_sha256: 31fa87bc7ee0d210ab5e0070b5421b72beac068fc006b3bc3be78b3dd242d5e7
output_file: model-outputs/generic_advice_prompted.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 01)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v11-v1`, condition `generic_advice_prompted`, run 1 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 105, on the frozen condition packet.

## Output

### Recommendation: Run the Claim File Review

You should recommend the **Claim File Review**.

#### Reasoning
Your current data is "noisy" and likely misleading. You are seeing a classic case of **lagging indicators (bookings/renewals) masking leading failures (usage patterns).**

1.  **The Revenue Mirage:** The 16% expansion rise is contaminated by a "bundle price" incentive. You aren't measuring the value of SignalPath; you are measuring the effectiveness of a discount strategy.
2.  **The Usage Mirage:** A 39% increase in usage is a vanity metric if the activity is primarily managers auditing closed files. This is "administrative usage," not "operational value."
3.  **The Adoption Gap:** The behavior of front-line adjusters (high initial use, then abandonment) suggests the tool provides a "novelty spike" but fails to integrate into the daily habit of claims handling.
4.  **The Compliance Wall:** In health-liability, the "explainability" gap is a fatal flaw. If an adjuster cannot defend a recommendation to a reviewer, the software becomes a liability rather than an asset.

The **Usage Quality Sprint** is too superficial; it tracks *if* they return, not *why* the output was rejected. The **Commercial Cleanroom** is too risky; it tests sales psychology, not product utility, and could jeopardize the momentum the board currently sees.

The **Claim File Review** is the only option that addresses the "Ground Truth." By auditing actual files, you move from *proxy metrics* (clicks and bookings) to *outcome metrics* (accepted vs. rewritten suggestions). This will tell you if SignalPath is actually solving the problem or if it is simply a "suggestion engine" that adjusters ignore once the novelty wears off.

#### The Tradeoffs
By choosing this, you are displacing **Scaling SignalPath Broadly**.

**What you give up:** You sacrifice the "momentum play." If SignalPath actually *is* a hit and you are just being overly cautious, you lose the first-mover advantage to capture more market share while the executive team is bullish. You risk a "cooling off" period where Sales feels Product is slowing down the commercial engine.

#### The Strongest Reason Against This Recommendation
The Claim File Review is slow, manual, and qualitative. It provides a "snapshot" rather than a real-time dashboard. There is a risk that the sample size will be too small to be statistically significant, leading the board to view the results as anecdotal while Sales continues to point at the (discount-driven) expansion bookings as "proof" of success.

#### Evidence That Would Change My Mind
I would pivot to **Narrowing the plan around regulated health-liability workflows** if the Claim File Review reveals that SignalPath’s core logic is fundamentally sound, but the "explainability" gap is the *only* reason for abandonment.

If the review shows that adjusters in non-regulated segments are also overriding suggestions (not just health-liability), the product has a general utility problem. But if non-regulated users are accepting suggestions at high rates and only health-liability users are struggling, the product is a success—it just requires a specialized "compliance/audit" layer to unlock its most lucrative and difficult segment.
